ArticleEClinicalMedicine2025
Adverse pregnancy and birth outcomes in women with biopsy-proven MASLD: a nationwide cohort study.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- MASLD, diabetes and PMOS across the female life stages.Diabetologia · 2026Review
- Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes.International journal of molecular sciences · 2026Review
- MASLD in Pregnancy: Rising Prevalence and Adverse Maternal and Perinatal Outcomes in a National Cohort, 2016-2022.Digestive diseases and sciences · 2026Article
- Increased global burden of metabolic dysfunction-associated steatotic liver disease is also seen in women of reproductive age.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Autoimmune disease in offspring of mothers with metabolic dysfunction-associated steatotic liver disease (MASLD): a nationwide cohort study.Scientific reports · 2026Article
- Higher Risk of Serious Infection in Offspring of Mothers With Biopsy-Proven MASLD: A Nationwide Cohort Study.United European gastroenterology journal · 2026Article
- Preexisting Liver Disease and Pregnancy: Optimizing Care to Optimize Outcomes.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Review
- Balancing metabolic optimization and reproductive safety in Polycystic Ovary Syndrome: a Bayesian-informed framework for GLP-1 receptor agonists.Frontiers in nutrition · 2026Review
- Mortality and Cancer in Offspring of Mothers With Biopsy-Proven MASLD During Pregnancy: A Nationwide Cohort Study.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has been linked to an increased risk of adverse pregnancy outcomes. We aimed to assess the roles of obesity, familial factors, and disease severity. Methods: Nationwide cohort study in Sweden (1992-2017) including 240 births (162 women) with biopsy-proven MASLD vs. 1140 matched reference births (1138 women). Multivariable conditional logistic regression determined adjusted odds ratios (aORs) for adverse pregnancy outcomes. Findings: Preterm birth occurred in 40 (16.7%) births of women with MASLD compared to 53 (4.7%) in reference births, yielding an aOR of 3.41 (95% CI = 1.98-5.88), which remained increased when compared with overweight/obese women without known MASLD (aOR = 4.60, 95% CI = 2.00-10.60). The association was observed for both medically indicated preterm birth (aOR = 11.90, 95% CI = 2.46-57.59) and spontaneous preterm birth (aOR = 2.42, 95% CI = 1.16-5.04). The aOR of preterm birth did not increase with MASLD severity (MASH without fibrosis/noncirrhotic fibrosis/cirrhosis: aOR = 1.53, 95% CI = 0.23-10.02), but 95% CIs were wide. MASLD was linked to increased odds of cesarean section (aOR = 1.63, 95% CI = 1.17-2.27), but not when compared with overweight/obese reference women (aOR = 1.20, 95% CI = 0.77-1.86). Our results indicate comparable Apgar scores, and similar rates of congenital malformation, stillbirth and neonatal death in both groups. Main results were confirmed in sibling analyses (i.e., when comparing to births of full female siblings of the mothers). Interpretation: MASLD is a risk factor for preterm birth, independent of obesity and familial factors. MASLD however does not indicate more stillbirths and neonatal deaths. We did not find more adverse pregnancy outcomes with increasing MASLD severity. Funding: Swiss National Science Foundation (P500PM_217670, P500PM_210866), European Crohn's and Colitis Organisation and, The Swedish Society for Medical Research (PG-23-0315-H-02) and Karolinska Institute.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.